Connect with us

Markets & Industry

UK’s Albert Labs receives conditional approval for CSE listing

Subject to approval, the Company is expected to commence trading under the ticker “ABRT” early in the new year.     



UK’s Albert Labs receives conditional approval for CSE listing

UK-based psychedelics company Albert Labs has received conditional approval for the listing of its common shares on the Canadian Securities Exchange (CSE).

Albert Labs made the announcement that it received conditional approval for the CSE listing of its common shares in co-ordination with its transaction with ME Resource Corp (MEC).

In June, MEC submitted an initial listing statement supporting its application for listing on the CSE in conjunction with its previously announced reverse take-over transaction with Albert Labs.

Through its clinical pathway focusing on Real World Evidence (RWE), Albert Labs will initially look to commercialise its mycelium-based KRN-101 medicine and treatment in a bid to bring psychedelic-assisted psychotherapy to patients.

Graeme McFarlane, chief commercial officer at Albert Labs, commented: “Albert Labs’ conditional listing takes us further towards our path of attracting investment to realise our vision of providing clinically proven pharma-grade psilocybin to meet the huge unmet need in treating patients with cancer-related distress – anxiety, depression, existential crisis. 

“This, together with our continued investment into our UK laboratory facility will strengthen our collaborations with UK academic institutions where we will be positioned to deliver on our promise.”

The company has also appointed one of Europe’s leading growth equity corporate finance and investment houses, Chrystal Capital Partners, to act as European capital markets adviser. Chrystal Capital will be advising Albert Labs on its proposed plans for a UK LSE dual listing.

Speaking on the appointment, founding partner of Chrystal Capital Partners, Kingsley Wilson, commented: “We have been very active in the legal medical cannabis space for five or six years now and have advised and arranged north of USD$450m in the sector. Cannabis is about mental health, wellness and healthcare generally, so, we started to look at psychedelics because a lot of investors and family offices have started to ask us about the space over the last couple of years.

See also  Where can I find training for psychedelic therapy?

“We wanted to make sure that the first psychedelics deal we did was close to home and has real relevance. But also, more importantly, a lot of the psychedelic companies we have seen are very early stage, looking to go through the pharmaceutical approach of discovering molecules and going through Phase I, II, and III trials and ultimately authroised products. That is great, but means there is long timelines with lots of capital that needs to be raised and a lot of risk in between.

“Albert Labs have a fantastic team behind them who really understand psychedelics, mental health and wellness, and really understand the regulatory pathways. Then we look at the business model, and Albert Labs is one that is more unique in the UK, exploring the Real World Evidence Studies regulatory pathway.

“The regulators are coming round to the view that things have to happen quicker in the pharmaceutical space, as there are millions of patients out there with unmet needs. So, we now have a somewhat unique situation where the UK regulatory authorities are looking to help early-stage companies like Albert Labs navigate a complex regulatory pathway with the aim of getting their product into trials and getting them licensed and authorised a lot quicker.

“Albert Labs can create API quality psilocybin and it has relationships with cancer clinics around the UK. The initial target is women with breast cancer suffering from depression and anxiety and other trauma-related feelings. This is a very serious issue, so, if we can get the products to those women, study the effects and do the trials, and hopefully prove that psilocybin has a very positive benefit, that then gives the ability to get to authorised and license products.

See also  Financial interests could corrupt psychedelics, says researcher 

“There are a million people in the UK and five million people around Europe that have unmet needs in this area and here comes a company with a product that can really make a huge difference and do it on a quicker timeline. So, for us and our investors, that is a really interesting and unique proposition.

“We are going to help Albert Labs raise CAD$4m and have now started the fundraising exercise. The money will go into the company at the same time it lists via its reverse take over on the CSE. Once we have done that we will start the process of engaging with respect UK advisors to bringing them to the market in London on one of the exchanges here.

“This is exciting, relevant and important – with this capital Albert Labs is going to go on to do some really valuable things. Both in terms of creating shareholder value, but also in providing products and treatments to millions of people who do not have any other solution. So, we see this as extremely worth and valuable.”

[activecampaign form=52]

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Markets & Industry

Psychedelic therapy programmes launch to address heartbreak, burnout and more



Psychedelic therapy programmes launch to address heartbreak, burnout and more

Mindbloom has launched its new Mastermind Series of psychedelic programmes for overcoming heartbreak, burnout and other unique mental health challenges. 

Led by and developed with leading experts in the field, each programme combines specialised teachings with ketamine therapy.

All programmes will include six ketamine therapy sessions focusing on a specific mental health issue, expert-led audio, video, and written content for preparation, treatment, and integration, practical tools such as meditation, one-on-one coaching and group integration sessions.

See also  Psychedelics for frontline workers, palliative care and eating disorders

The first programme in the Series is ‘Recovering from Rejection and Failure’, led by Dr Guy Winch who is a leading authority on emotional health, and a best-selling author and TED speaker whose talks have received over 30 million views.

Winch’s programme focuses on healing and preventing emotional injuries that people suffer in their personal, professional and romantic lives.

Mindbloom CEO and Founder Dylan Beynon stated: “More than 100 studies and 20 plus years of clinical use show that ketamine therapy may be the most transformational mental health treatment available today.

“In the face of epidemics of mental illness, addiction, and loneliness, we’re thrilled to offer our clients access to top experts across a range of issues – and to pair their expertise with our best-in-class ketamine therapy honed over hundreds of thousands of treatment sessions.”

“Emotional wounds like rejection and failure can be even more devastating than physical wounds, yet we don’t give them the same time and attention,” added Dr Winch.

“I’m thrilled to combine my techniques for emotional first aid with ketamine therapy, which has been shown to increase neuroplasticity and help build emotional resilience.”

Additional Mastermind programmes will be released in the coming months, including: Getting Unstuck, by Dr Elizabeth Lombardo; Beating Burnout, by Dr Shauna Shapiro; and Coping with Cravings, by Dr Jud Brewer

“Americans are struggling with heartbreak, burnout, and other challenges every day, and they’re looking for new tools to address them,” said Mindbloom’s Medical Director Dr Leonardo Vando.

“I’m grateful to these experts for providing Mindbloom’s clients with the unique practices and insights they’ve cultivated during their distinguished careers, to help them overcome the biggest obstacles in their lives.”

Continue Reading

Markets & Industry

Mychedelica launches to revolutionise psychedelic medicine



Mychedelica launches to revolutionise psychedelic medicine

A new company specialising in psychedelic medicine – mychedelica – is offering a comprehensive suite of services to support the advancement of this transformative field. 

With a team of experienced medical writers and research support specialists, mychedelica is committed to providing the highest quality services to researchers, clinicians, and pharmaceutical companies working in the psychedelic medicine space.

Psychedelic medicine is rapidly gaining recognition for its potential to treat a wide range of mental health conditions, including depression, anxiety, addiction, and post-traumatic stress disorder (PTSD). However, the field is still in its early stages of development, and there is a critical need for high-quality medical writing and research support services to facilitate its progress.

CEO of mychedelica, Bilal Bham, commented: “We are thrilled to launch mychedelica and contribute to the advancement of psychedelic medicine.

“Our team of experienced professionals is dedicated to providing the highest quality services to researchers, clinicians, and pharmaceutical companies working in this groundbreaking field.”

mychedelica provides a comprehensive range of services, including:

Medical writing: Experienced medical writers will craft clinical trial protocols, regulatory submissions, and peer-reviewed publications, ensuring that research findings are communicated clearly and effectively.

Funding research support: Experts in grant writing and fundraising strategies will assist researchers in securing funding for their psychedelic medicine studies.

Regulatory consulting: mychedelica’s team of regulatory experts will navigate the complex regulatory landscape surrounding psychedelic medicine, ensuring that clinical trials and products comply with all applicable laws and regulations.

With its commitment to quality and innovation, mychedelica is poised to play a pivotal role in shaping the future of psychedelic medicine. The company’s services will empower researchers to conduct rigorous clinical trials, clinicians to provide effective treatments, and pharmaceutical companies to develop safe and effective psychedelic medicines.

Continue Reading

Markets & Industry

Short Wave Pharma: innovating eating disorder care with psychedelics



Short Wave Pharma: innovating eating disorder care psychedelics

Psychedelic Health speaks to Short Wave Pharma CEO Rivki Stern about the company’s plans to innovate eating disorder care through psychedelics and its recent acquisition by Psych Capital.

Short Wave Pharma was recently acquired by global investment firm Psych Capital. The companies are on a mission to transform mental health care, focusing on innovative approaches and treatments, including psychedelics, which are increasingly gaining acceptability as clinical research results accumulate.

Short Wave Pharma’s clinical programmes are particularly focused on Anorexia nervosa – a complex mental health condition with one of the highest fatality rates. Despite the condition being associated with high rates of suicide, it is a hugely underserved area of mental health, with no FDA-approved pharmacological drug, and a high rate of chronicity. 

See also  Psych Capital completes acquisition of Short Wave Pharma

The company has developed a novel delivery method and drug combination specifically designed to address the requirements of this vulnerable population. Short Wave focuses on methods of delivery that will be effective for Anorexia, which is a metabolic disease as well as a mental health condition. Its unique buccal film delivery method is intended to affect the brain while bypassing the liver and gut degradation through mucoadhesive absorption.

“Our goal is to alleviate, solve, and treat mental health conditions. It’s a dire need in our global society, and it’s constantly on the rise,” commented Stern. “Eating disorders are a very good example of that and we have seen a very alarming growth since COVID. 

“What drew our attention to psychedelics is that they have the potential to address very complex mental health diseases and have been designated by FDA as breakthrough medicine for life-threatening conditions.

“Because there are no current solutions, we must harness very innovative approaches and potential solutions. That’s why we started working with psychedelics which may be difficult because they are not regulated, but we don’t shy away from challenges.”

The company’s drug is based on psilocybin and another API which together utilise an expanded mechanism of action and a therapeutic effect superior to psilocybin alone, impacting more than one group of receptors in the brain. 

The delivery method is sensitive to the patients’ needs – who may not want to swallow or be injected – and is known for its high bioavailability. 

“By mucosal absorption, we are speeding the onset of the medicine and amplifying the impact which will help tackle the patients’ metabolic challenges and improve acceptance,” says Stern. 

The drug product and delivery method are currently in preparation for Phase 1 clinical studies, and in its current preclinical studies, the company is validating its delivery and expanded mechanisms of action. So far, initial safety results are positive, with a further, more in-depth toxicity study taking place. 

Psych Capital – which is a public investment and awareness platform for mental health, and has a portfolio of innovative companies – has supported Short Wave Pharma’s IP-driven approach to eating disorder care through its recent acquisition of the company.

Short Wave and Psych Capital say they are aligned in their missions to innovate mental healthcare and deliver transformative care in areas of high unmet need.

Stern commented: “We all share a passion for innovation and together have decades of experience in evaluating investments as well as scaling up R&D projects and start-ups in life sciences. 

“We have a shared commitment to alleviate the suffering from mental health. Every one of us has experienced the frustration and challenges of dealing with mental health issues.

“Together, we’re going to put this commitment into action, by bringing forth innovative solutions and developments and getting them through the first stages of development, from discovery through to early phases of clinical study. 

“With psychedelics components, this is extra challenging because of their status as scheduled drugs within a still evolving regulatory framework, which adds uncertainty to the drug development process. 

“Short Wave Pharma has operational expertise in early-stage drug development which will bring extra value to the group’s projects as they develop through our funnel and grow into promising candidates for mental healthcare.  

“We want to identify the gems, guide them through clinical development, and create the right network to attract the right partners for further development and commercialisation.”

Short Wave Pharma is planning to enter its treatment into clinical studies in 2024.

Continue Reading